Creative Bio-Peptides, Inc.
Rockville, MD
- UEI
- KXWAKDEXPKM3
- CAGE
- 83HH1
- SAM.gov registration
- Active through
Company facts
- Self-certified in SAM.gov
- Entity structure
- Corporate Entity (Not Tax Exempt)
- SAM.gov registration date
- Physical address
- 10319 Glen Rd, Rockville, MD 20854, USA
- Website
- creativebiopeptides.com
- Founded
- 2017
- Employees
- 1-10
- Estimated annual revenue
- $1M-$10M
- Industry
-
- Health Care
- Pharmaceuticals, Biotechnology & Life Sciences
- Pharmaceuticals
- SIC code
- 28 Chemical & Allied Products
- Profiles
Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .
Grant awards
Latest 5 listed here. See the rest on GovTribe.
Similar vendors
| Vendor | Location | Primary NAICS |
|---|---|---|
| Proneurogen Inc. | Tucson, AZ | 541714 Research and Development in Biotechnology (except Nanobiotechnology) |
| Raft Pharmaceuticals LLC | San Diego, CA | 541714 Research and Development in Biotechnology (except Nanobiotechnology) |
| Velum Inc. | Cambridge, MA | — |
| Janusq LLC | Rocky River, OH | — |
| Regulonix LLC | Gainesville, FL | 541714 Research and Development in Biotechnology (except Nanobiotechnology) |
About the company
Creative Bio-Peptides, Inc., doing business as Creative Bio-Peptides Inc., is a pharmaceutical manufacturing company that specializes in developing safe and effective medicines for the treatment of neuropathies and neurological diseases. Its founder, Dr. Michael Ruff, has pioneered the use of oral receptorantagonist peptides to address neurodegenerative diseases.
Creative Bio-Peptides, Inc. has received several multi-million dollar federal grant awards from agencies like the National Institutes of Health (NIH) to fund research and development of novel chemokine receptor antagonist peptides as treatments for various conditions. Under the NIH's Aging Research, Drug Abuse and Addiction Research, and Neurological Disorders programs, Creative Bio-Peptides has worked on non-opioid treatments for chronic pain relief in diabetic peripheral neuropathy and chemotherapy-induced neuropathy. It is developing therapies using peptides like RAP-103 and R103 to protect synapses and potentially reverse cognitive deficits in Alzheimer's disease and related dementias by blocking receptors implicated in neuroinflammation and synapse loss. The company is also investigating chemokine antagonist peptides to treat opioid use disorder by reducing opioid reinforcement, relapse, withdrawal symptoms, and cravings without the risks of current medication-assisted treatments. Creative Bio-Peptides conducts preclinical studies in vitro and in animal models and undertakes manufacturing scale-up, pharmacokinetic/toxicity testing, and regulatory activities to advance promising candidates towards clinical trials.
Quick answers
Is Creative Bio-Peptides, Inc. registered in SAM.gov?
Yes. Creative Bio-Peptides, Inc.'s SAM.gov registration is active through June 8, 2027.
What is Creative Bio-Peptides, Inc.'s most recent federal award?
Creative Bio-Peptides, Inc.'s most recent federal grant award is Pet imaging to evaluate a novel chemokine antagonist to protect synapses in adrd - 7. Project summary adrd dementias… (R43AG085779), from National Institute on Aging (NIH), on September 30, 2023.
On GovTribe
See Creative Bio-Peptides, Inc.'s full federal record
- Federal grant awards
- Funding analysis by agency, NAICS and set-aside
- Similar vendors